Emerging Tx for Adv EC

CME

Emerging Therapies for Advanced Endometrial Cancer

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: September 18, 2023

Expiration: September 17, 2024

Hye Sook Chon
Hye Sook Chon, MD
Ritu Salani
Ritu Salani, MD, MBA

Activity

Progress
1
Course Completed

References

  1. Makker V, MacKay H, Ray-Coquard I, et al. Endometrial cancer. Nat Rev Dis Primers. 2021;7:88.
  2. Surveillance, Epidemiology, and End Results. Cancer stat facts: uterine cancer. seer.cancer.gov/statfacts/html/corp.html. Accessed September 6, 2023.
  3. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73. 
  4. León-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38:3388-3397.
  5. Pasanen A, Ahvenainen T, Pellinen T, et al. PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups. Am J Surg Pathol. 2020;44:174-181.
  6. Li Y, Feng J, Zhao C, et al. A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers. Ann Transl Med. 2022;10:870.
  7. Corr B, Cosgrove C, Spinosa D, et al. Endometrial cancer: molecular classification and future treatments. BMJ Med. 2022;1:e000152.
  8. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: uterine neoplasms.
    v.2.2023. nccn.org. Accessed September 6, 2023.
  9. Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388:2159-2170.
  10. Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388:2145-2158.
  11. Pembrolizumab [prescribing information]. North Wales, PA: Merck, Sharp and Dohme Corporation, a subsidiary of Merck & Co., Inc.; 2023.
  12. Dostarlimab [prescribing information]. Collegeville, PA: GlaxoSmithKline LLC; 2023.
  13. Miller DS, Filiaci VL, Manne RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 38:3841-3850.
  14. Seghers PAL, Wiersma A, Festen S, et al. Patient preferences for treatment outcomes in oncology with a focus on the older patient—a systematic review. Cancers (Basel). 2022;14:1147.
  15. Bogani G, Monk BJ, Coleman RL, et al. Selinexor in patients with advanced and recurrent endometrial cancer. Curr Probl Cancer. 2023;[Epub ahead of print].
  16. Slomovitz BM, Perez-Fidalgo JA, Hamilton EP, et al. Long-term follow up of selinexor maintenance in patients with TP53wt advanced or recurrent endometrial cancer: a pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study. Presented at: ASCO Plenary Series; July 25, 2023. Abstract 427956.
  17. Vergote I, Pérez Fidalgo A, Hamilton E, et al. SIENDO/ENGOT-EN5/GOG-3055: a randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer. Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Abstract 249.
  18. Selinexor [prescribing information]. Newton, MA: Karyopharm Therapeutics Inc.; 2022.
  19. Buza. HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand. Arch Pathol Lab Med. 2020;145:687-691.
  20. Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2022.
  21. Nishikawa T, Hasegawa K, Matsumoto K, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2–expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial. J Clin Oncol. 2023;41:2789-2799.
  22. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract LBA300.